Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioTools Bridges the Empirical: Computational Chemistry Chasm with ComputeVOA

Published: Thursday, June 06, 2013
Last Updated: Wednesday, June 05, 2013
Bookmark and Share
ComputeVOA uses Vibrational Circular Dichroism to determine the three-dimensional structure of chiral molecules.

Chiral molecules, those “left/right” mirror image marvels of nature, determine much of our biology and, as a result, are of prime interest to biologists, organic chemists, and especially, the pharmaceutical industry.

But which of the left/right stereoisomers has the optimum chemical activity? BioTools (Jupiter, FL) answers that question.

They capitalized on the recent American Chemical Society meeting (April 7-10, New Orleans, LA) to launch ComputeVOA, an innovative, easy-to-use software package which uses Vibrational Circular Dichroism (VCD) to determine the three-dimensional structure of chiral molecules and their predicted spectra.

“Chirality and the resulting molecular behavior is a hot topic for many students and practicing organic and pharmaceutical chemists,” cited BioTools’ President, Dr. Rina Dukor.

Dr. Dukor continued, “They all have chemical drawing programs. ComputeVOA empowers them to take the next steps: select an actual 3D structure, determine the energy optimizations, identify the potential stereo isomer structure (called a ‘conformer’), then calculate its IR and VCD spectra.”

Once plotted, the calculated spectra can then be compared to an empirically measured spectra, providing an unambiguous determination of the molecule’s absolute stereo-specific structure, saving years of experimental time and expense.

Pharma has been an early VCD adopter, propelled by the need to define three-dimensional structure and the resulting biological activity of drug candidates as early as possible in the product development process.

According to a GIA report on the Chiral Technology Market (April 2012), by 2020, 95% of all pharmaceutical drugs will be chiral. The driving factor: greater therapeutic effectiveness of single-enantiomer compounds.

In the most successful companies, analytical chemists have partnered with senior computational chemists to achieve these calculations, often using three or four programs, or even writing their own, to model molecules.

“The new software changes all of that,” explains Dr. Dukor. “With the exception of very complex molecules, ComputeVOA provides one, facile platform which opens access to chiral characterization across the analytical spectrum, from students and entry level scientists to technicians and general analytical chemist.”

ComputeVOA orchestrates a complex molecular dance. Data enters the stream through a molecule builder/structure importer then moves into a robust molecular mechanics conformational search algorithm.

The results then pass through a transparent handshake to Gaussian 09 (Gaussian, Inc. Pittsburgh, PA) where quantum mechanics determines the molecule’s structure and properties.

It then returns seamlessly to ComputeVOA for a Boltzmann-averaging of conformers and plotting of the IR and VCD spectra.

The final output: The specific stereo isomers’ 3D structure and accompanying InfraRed and Vibrational Circular Dichroism spectra.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.
Game Changing Antibacterial Drug Research
Researchers publish report on the synthesis of a newly discovered “game-changing” antibiotic, Teixobactin.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
New Way of Displaying 3D Molecular Structures
Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples.
Agent Blocks Pain Without Morphine's Side Effects
Scientists have synthesised a molecule with specific pain-relief properties and has shown its efficacy in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!